Subject Index

Activity, Graves’ orbitopathy
  clinical assessment 8–11, 83
  definition 6, 7, 81, 82
  laboratory tests 13, 14
  management guidelines 13
Age
  distribution of Graves’ orbitopathy 35
  effects on Graves’ orbitopathy
    presentation 4
Anterior orbital septum (AOS) 5
Antithyroid drug therapy, Graves’
  orbitopathy outcomes 100, 101, 103
Apical crowding, imaging 59–61
Artificial tears, Graves’ orbitopathy
  management 90
Azathioprine, moderately severe Graves’
  orbitopathy management 140–142
Botulinum toxin, Graves’ orbitopathy
  management 91, 189, 190
Caroticocavernous fistula, differential
  diagnosis 75
Caruncle, inflammation assessment 10, 11
CD20, therapeutic targeting 238–240
Chemosis, assessment 9
Childhood Graves’ orbitopathy
  clinical presentation 222
  epidemiology 222, 223
  severity 222–224
  treatment 224–226
Ciameixone, moderately severe Graves’
  orbitopathy management 140, 142
Clinical Activity Score (CAS) 11, 12, 83
Color vision, assessment 18, 19
Combined thyroid-eye clinic
  definition 96, 97
  fast-track for Graves’ orbitopathy patients
    98, 99
  multidisciplinary approach advantages
    97, 98
  patient support groups 98
Computed tomography (CT)
  Graves’ orbitopathy diagnosis 71
  orbital imaging 57–59
Conjunctival edema, see Chemosis
Conjunctival redness, assessment 8, 9
Corneal ulceration
  Clinical Activity Score 11, 12
  eyelid surgery 190
  Graves’ orbitopathy diagnosis 69
  overview 3, 6
Corticosteroids, see Steroid therapy
Cosmetic surgery, definition 160
CTLA-4
  Graves’ orbitopathy susceptibility locus 86
  therapeutic targeting 53, 239
Cyclosporine, moderately severe Graves’
  orbitopathy management 138, 139
Delayed decompression-related reactivation
  (DDRR) 172
Diabetes, Graves’ orbitopathy risks 38, 39
Diagnosis, Graves’ orbitopathy
  clinical findings
    corneal ulceration 69
Diagnosis, Graves’ orbitopathy (continued)  
clinical findings (continued)  
eyeball motility restriction 69  
eyelid retraction 68  
eyelid swelling 67, 68  
proptosis 69  
visual acuity 69, 70  
criteria 70  
errors in complex cases 178, 179  
laboratory tests 70, 71  
overview 66  
Differential diagnosis  
caroticocavernous fistula 75  
non-Hodgkin lymphoma 76  
onorbital meningioma 72  
orbital myositis 72–74  
Diplopia, orbital decompression surgery  
complication 173  
Diuretics, Graves’ orbitopathy management 91  
Double vision 1, 173  
Dysthyroid optic neuropathy (DON)  
apical crowding imaging 59–61  
appearance 18–23, 156  
blindness outcomes 158  
clinical features 2, 3, 6, 154, 155  
definition 153  
evidence-based management 157  
ophthalmological signs 155  
risk factors 22, 153  
surgical management 157, 158  
urgent treatment indications 156, 157  
vision effects 22  
Epidemiology, Graves’ orbitopathy  
age and sex distribution 35  
childhood Graves’ orbitopathy 222, 223  
comorbidity  
non-ocular 38, 39  
ocular 37, 38  
etnic differences 35  
prevalence 34, 35  
risk factors 35, 36  
trends 34, 35  
Euthyroid Graves’ orbitopathy, management 218  
Evidence-based medicine  
dysthyroid optic neuropathy management 157  
historical perspective 252, 253  
mildly to moderately severe Graves’ orbitopathy  
management 148, 149  
Eyelid erythema, assessment 8  
Eyelid retraction  
differential diagnosis 68  
Graves’ orbitopathy diagnosis 68  
Eyelid surgery  
complications 195–198  
debulking and blepharoplasty 198  
indications 188–190  
orbital decompression effects on lid  
retraction 190, 191  
spacer materials 196, 197  
squint surgery influence on lid  
configuration 191, 192  
techniques  
lower lid 196  
upper lid 193–195  
Eyelid swelling  
assessment 9, 10  
differential diagnosis 67  
Graves’ orbitopathy diagnosis 67, 68  
Eye muscle surgery  
affected muscle identification 176–178  
complications 185, 186  
extpectations and outcomes 182, 183  
indications 179–182  
planning 183–185  
timing 182  
Fibroblast, therapeutic targeting 52, 53  
Fluorometholone, Graves’ orbitopathy  
management 90  
Fundoscopy, optic neuropathy assessment 19  
Genetic susceptibility, Graves’ orbitopathy 4, 50, 51  
Glaucoma, see Primary open-angle  
glaucoma  
Globe subluxation 1, 219  
Glucocorticoids, see Steroid therapy  
Graves’ disease  
Graves’ orbitopathy frequency 29  
localised myxedema 31, 32  
thyroid acropachy 32  
Graves, Robert James 246
Guanethidine, Graves’ orbitopathy management 91

Hyaluronic acid, lower lid injection 243

Hyperthyroidism
  Graves’ orbitopathy relationship 27–29, 78, 89
  history of study with proptosis 248, 249

Hypothyroidism
  Graves’ orbitopathy relationship 79, 80, 89
  transient hypothyroidism after hyperthyroidism treatment 105, 106

Insulin-like growth factor-1 (IGF-1) receptor
  antibodies and Graves’ orbitopathy 47 therapeutic targeting 239

Interleukin-1 (IL-1), therapeutic targeting 53, 239

Interleukin-6 (IL-6), therapeutic targeting 53, 239

Intravenous immunoglobulin (IVIg), moderately severe Graves’ orbitopathy management 139, 140, 142, 143

Ketorolac, Graves’ orbitopathy management 90

Lantreotide, see Somatostatin analogs

Magnetic resonance imaging (MRI)
  Graves’ orbitopathy diagnosis 71
  orbital imaging 58, 59, 63

Mild Graves’ orbitopathy
  antioxidant therapy 116, 117
  intra-orbital involvement 111
  oral steroid therapy 114
  progression 111, 112
  radiation therapy 115, 116
  treatment versus wait and see 112, 113

Moderately severe Graves’ orbitopathy
  azathioprine therapy 140–142
  ciamexone therapy 140, 142
  combination steroid and radiotherapy 135–138
  cyclosporine therapy 138, 139
  evidence-based therapeutic recommendations 148, 149
  immunosuppression indications 120, 121
  intravenous immunoglobulin therapy 139, 140, 142, 143
  intravenous steroid therapy adverse effects 130
  outcomes 126–130
  oral steroid therapy 121–125
  radiation therapy
    outcomes 131–133
    protocol 133, 134
    safety 134, 135
  retrobulbar injection of steroids 130
  somatostatin analog therapy 144–147

Myasthenia gravis (MG), Graves’ orbitopathy risks 39

Myxedema, Graves’ disease association 31, 32

Natural history, Graves’ orbitopathy
  ‘burn’ out 84, 85
  euthyroidism restoration 78, 79
  hyperthyroidism 78
  hypothyroidism 79, 80
  mild disease progression 111, 112
  modifying factors 85, 86
  recurrence 85
  return to normality 84, 85
  Rundle’s curve 80
  treatment guidance 83, 84
  typical course 80, 81

Non-Hodgkin lymphoma, differential diagnosis 76

NOSPECS classification
  class frequencies 14–16
  overview 14, 15
  severity assessment 14, 16–20, 83

Octreoscan, orbital imaging 62

Octreotide, see Somatostatin analogs

Ocular motility impairment
  affected muscle identification 176–178
  Graves’ orbitopathy diagnosis 69
  mechanisms on Graves’ orbitopathy 176
  presentation 3
  surgery, see Eye muscle surgery
Subject Index

Optic neuropathy, see Dysthyroid optic neuropathy

Orbit
imaging
apical crowding 59–61
computed tomography 57–59
indications 57
magnetic resonance imaging 58, 59, 63
octreoscan 62
positron emission tomography 64
ultrasonography 61, 62
immune reactions 48–50
thyroid autoimmunity and orbit pathology 47

Orbital decompression surgery
aims
functional aims 164, 165
rehabilitative symptomatic aims 165–167

childhood Graves’ orbitopathy management 226

complications
delayed decompression-related reactivation 172
prevention 172, 173
dysthyroid optic neuropathy management 157, 158

lid retraction effects 190, 191
overview 163
prospects 241–243

technique
fat removal 167, 170, 171
osteotomy 167, 170, 171
rehabilitative surgery 168, 169

Orbital meningioma, differential diagnosis 72

Orbital myositis, differential diagnosis 72–74

Parry, Caleb Hillier 246

Pathogenesis, Graves’ orbitopathy
clinical manifestation mechanisms 5, 6, 44, 45
orbital tissue pathology
adipogenesis 43
early inflammatory changes 42, 43
glycosaminoglycan production 43, 44

overview 41, 42
triggers 45–47

Patient support groups 98

Pentoxifylline, mild Graves’ orbitopathy management 116

Perimetry, optic neuropathy assessment 19

Photophobia 1

Plica, inflammation assessment 10, 11

Positron emission tomography (PET), orbital imaging 64

Prevalence, Graves’ orbitopathy and trends 34, 35

Prevention, Graves’ orbitopathy
general strategy 229, 230
primary prevention 230, 231
primary, secondary, and tertiary prevention definitions 229
secondary prevention 231–233
tertiary prevention 233, 234

Primary open-angle glaucoma (POAG), Graves’ orbitopathy risks and management 37, 38

Proptosis
assessment 20
differential diagnosis 69
Graves’ orbitopathy diagnosis 69

Ptosis 3

Pupil response 19

Quality of life (QoL)
definition 201
Graves’ orbitopathy
GO-QoL questionnaire
components 204–206
findings 206
recommendations 209, 210
therapeutic outcome measurement 207, 208
health-related quality of life 203, 204
response shift 206, 207
restoration after treatment 208, 209
usefulness of measurements 201–203

Race
effects on Graves’ orbitopathy
presentation 4
Subject Index

epidemiology of Graves’ orbitopathy 35

Radiation therapy
mild Graves’ orbitopathy management 115, 116
moderately severe Graves’ orbitopathy management
combination steroid and radiotherapy 135–138
outcomes 131–133
protocol 133, 134
safety 134, 135
response classification 252

Radioiodine
childhood Graves’ orbitopathy management 225
Graves’ orbitopathy outcomes 101–104
Graves’ orbitopathy trigger 45
guidelines 106
risk factors in Graves’ orbitopathy progression 233
total thyroid ablation 107, 108

Rehabilitative surgery
definition 160
orbital decompression surgery, see Orbital decompression surgery
patient selection 161, 162
steps 161
timing 161

Rituximab, Graves’ orbitopathy management 238–240
Rundle, F.F. 249–252
Rundle’s curve 80, 249

Severity, Graves’ orbitopathy
assessment 14, 16–20, 83
childhood Graves’ orbitopathy 222–224
definition 6, 7, 82, 83
treatment guidance 92, 93

Sex distribution, Graves’ orbitopathy 35, 36, 86

Signs, Graves’ orbitopathy
common signs 1, 2
history of study 247, 248
severity assessment 14
unusual signs 2, 3

Smoking
cessation
benefits 89
promotion 234
Graves’ orbitopathy risks 36, 51, 52, 85, 86
primary prevention of Graves’ orbitopathy 230, 231
secondary prevention of Graves’ orbitopathy 233

Somatostatin analogs
childhood Graves’ orbitopathy management 225
moderately severe Graves’ orbitopathy management 144–147

Steroid therapy
mechanism of action 237, 238
mild Graves’ orbitopathy 114
moderately severe Graves’ orbitopathy combination steroid and radiotherapy 135–138
intravenous steroid therapy adverse effect 130
outcomes 126–130
oral steroid therapy 121–125
retrobulbar injection 130

Strabismus, see Ocular motility impairment

Surgery, see Eyelid surgery; Eye muscle surgery; Orbital decompression surgery; Rehabilitative surgery

Symptoms, Graves’ orbitopathy 1

Thyroglobulin, antibodies in Graves’ orbitopathy 46

Thyroid acropachy, Graves’ disease association 32

Thyroidectomy
childhood Graves’ orbitopathy management 225
Graves’ orbitopathy outcomes 102, 103, 107, 108

Thyroid-stimulating hormone (TSH) receptor antibodies and Graves’ orbitopathy 30, 31, 46, 47, 50, 70, 71, 85
therapeutic targeting 241

Trauma, Graves’ orbitopathy trigger 45
Tumor necrosis factor-α (TNF-α), therapeutic targeting 53, 238, 239

Ultrasonography, orbital imaging 61, 62

Unilateral Graves’ orbitopathy
  clinical presentation 217
  mechanisms 212–216

progression to bilateral disease 216, 217
  treatment 217, 218

Very severe Graves’ orbitopathy, see Dysthyroid optic neuropathy

von Basedow, Karl Adolph 246